Updated results from a Phase I/II trial of golcadomide ± rituximab in R/R FL

Julio Chavez, MD, Moffitt Cancer Center, Tampa, FL, comments on the updated results from the Phase I/II CC-99282-NHL-001 study (NCT03930953), which investigated golcadomide plus rituximab in patients with relapsed/refractory follicular lymphoma (R/R FL). The study showed an impressive response rate, and while data on progression-free survival is still immature, the results are encouraging. The combination was safe, with the most common side effect being neutropenia, which was manageable with growth factors. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.